US Representative

Darin LaHood Authored & Sponsored Legislation

Session

Co-Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB575

Introduced
1/21/25  
Refer
1/21/25  
Increased TSP Access Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB591

Introduced
1/21/25  
Defending American Jobs and Investment Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB6

Introduced
1/3/25  
Family and Small Business Taxpayer Protection Act This bill rescinds unobligated funds that were provided by the Inflation Reduction Act of 2022 to the Internal Revenue Service (IRS) for enforcement activities related to the determination and collection of taxes, for operations support for taxpayer services and enforcement activities, and for a task force to research options for a free, direct electronic filing (e-filing) tax return system. The bill also rescinds unobligated funds that were provided by the Inflation Reduction Act of 2022 for expenses of theTreasury Inspector General for Tax Administration,Office of Tax Policy,U.S. Tax Court, andoffices within the Department of the Treasury that provide oversight and support for the IRS.  
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB640

Introduced
1/22/25  
Chemical Tax Repeal Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB662

Introduced
1/23/25  
Promoting Domestic Energy Production Act
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB682

Introduced
1/23/25  
Heartbeat Protection Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB685

Introduced
1/23/25  
Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB7

Introduced
1/22/25  
No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025
US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB703

Introduced
1/23/25  
Main Street Tax Certainty Act

Primary Sponsor of Legislation

US

Us Congress 2025-2026 Regular Session

Us Congress House Bill HB623

Introduced
1/22/25  
Refer
1/22/25  
LICENSE Act of 2025 Licensing Individual Commercial Exam-takers Now Safely and Efficiently Act of 2025